![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PAEP |
Gene summary for PAEP |
![]() |
Gene information | Species | Human | Gene symbol | PAEP | Gene ID | 5047 |
Gene name | progestagen associated endometrial protein | |
Gene Alias | GD | |
Cytomap | 9q34.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B4E3C0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5047 | PAEP | HCC2 | Human | Liver | HCC | 2.91e-02 | 2.48e+00 | 0.5341 |
5047 | PAEP | S027 | Human | Liver | HCC | 9.45e-26 | 1.37e+00 | 0.2446 |
5047 | PAEP | S028 | Human | Liver | HCC | 3.51e-22 | 6.50e-01 | 0.2503 |
5047 | PAEP | S029 | Human | Liver | HCC | 3.97e-33 | 1.19e+00 | 0.2581 |
5047 | PAEP | ATC09 | Human | Thyroid | ATC | 1.15e-66 | 2.73e+00 | 0.2871 |
5047 | PAEP | ATC1 | Human | Thyroid | ATC | 1.81e-66 | 2.99e+00 | 0.2878 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000181924 | Thyroid | ATC | positive regulation of cytokine production | 189/6293 | 467/18723 | 1.00e-03 | 5.31e-03 | 189 |
GO:00107216 | Thyroid | ATC | negative regulation of cell development | 76/6293 | 180/18723 | 9.50e-03 | 3.49e-02 | 76 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PAEP | SNV | Missense_Mutation | rs570771664 | c.314N>T | p.Thr105Met | p.T105M | P09466 | protein_coding | tolerated(0.24) | benign(0.014) | TCGA-B6-A0RL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PAEP | SNV | Missense_Mutation | novel | c.256N>C | p.Glu86Gln | p.E86Q | P09466 | protein_coding | tolerated(0.15) | possibly_damaging(0.615) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
PAEP | SNV | Missense_Mutation | c.317T>C | p.Val106Ala | p.V106A | P09466 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PAEP | SNV | Missense_Mutation | novel | c.447N>T | p.Glu149Asp | p.E149D | P09466 | protein_coding | deleterious(0.04) | possibly_damaging(0.871) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PAEP | SNV | Missense_Mutation | c.350N>G | p.Tyr117Cys | p.Y117C | P09466 | protein_coding | deleterious(0.02) | benign(0.395) | TCGA-AP-A05N-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PAEP | SNV | Missense_Mutation | c.287N>G | p.Asn96Ser | p.N96S | P09466 | protein_coding | tolerated(0.79) | benign(0.137) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
PAEP | SNV | Missense_Mutation | rs570771664 | c.314C>T | p.Thr105Met | p.T105M | P09466 | protein_coding | tolerated(0.24) | benign(0.014) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PAEP | SNV | Missense_Mutation | rs754340819 | c.451N>G | p.Met151Val | p.M151V | P09466 | protein_coding | tolerated(0.11) | possibly_damaging(0.654) | TCGA-BG-A221-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PAEP | SNV | Missense_Mutation | novel | c.303N>T | p.Lys101Asn | p.K101N | P09466 | protein_coding | tolerated(0.22) | benign(0.065) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PAEP | SNV | Missense_Mutation | novel | c.470N>T | p.Ala157Val | p.A157V | P09466 | protein_coding | tolerated(0.75) | possibly_damaging(0.794) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5047 | PAEP | DRUGGABLE GENOME | GENISTEIN | GENISTEIN | 12820358 | |
5047 | PAEP | DRUGGABLE GENOME | CYPROTERONE ACETATE | 1388220 |
Page: 1 |